- Home
- EOI vs ATXS Comparison
EOI vs ATXS Comparison
Compare EOI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOI
- ATXS
- Stock Information
- Founded
- EOI 2004
- ATXS 2008
- Country
- EOI United States
- ATXS United States
- Employees
- EOI N/A
- ATXS N/A
- Industry
- EOI Finance/Investors Services
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- EOI Finance
- ATXS Health Care
- Exchange
- EOI Nasdaq
- ATXS Nasdaq
- Market Cap
- EOI 827.9M
- ATXS 669.8M
- IPO Year
- EOI N/A
- ATXS 2015
- Fundamental
- Price
- EOI $20.59
- ATXS $9.37
- Analyst Decision
- EOI
- ATXS Strong Buy
- Analyst Count
- EOI 0
- ATXS 5
- Target Price
- EOI N/A
- ATXS $25.60
- AVG Volume (30 Days)
- EOI 83.6K
- ATXS 219.2K
- Earning Date
- EOI 01-01-0001
- ATXS 11-13-2024
- Dividend Yield
- EOI 7.19%
- ATXS N/A
- EPS Growth
- EOI N/A
- ATXS N/A
- EPS
- EOI N/A
- ATXS N/A
- Revenue
- EOI N/A
- ATXS N/A
- Revenue This Year
- EOI N/A
- ATXS N/A
- Revenue Next Year
- EOI N/A
- ATXS N/A
- P/E Ratio
- EOI N/A
- ATXS N/A
- Revenue Growth
- EOI N/A
- ATXS N/A
- 52 Week Low
- EOI $14.36
- ATXS $4.26
- 52 Week High
- EOI $18.88
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- EOI 57.12
- ATXS 30.44
- Support Level
- EOI $20.43
- ATXS $11.40
- Resistance Level
- EOI $20.85
- ATXS $11.75
- Average True Range (ATR)
- EOI 0.27
- ATXS 0.75
- MACD
- EOI 0.01
- ATXS -0.23
- Stochastic Oscillator
- EOI 69.05
- ATXS 7.64
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.